INVO Fertility 2025 Q3 Earnings Narrowed Per-Share Losses Despite Wider Net Loss

INVO Fertility (IVF) reported fiscal 2025 Q3 results on November 17, 2025, showing revenue growth but persistent losses. The company narrowed its per-share loss by 94.9% to $0.77, while net losses widened by 62.2% to $2.64 million. Management emphasized strategic acquisitions and operational efficiencies as growth drivers.

Revenue

The total revenue of INVO Fertility surged 22.6% to $1.76 million in 2025 Q3, up from $1.43 million in 2024 Q3. Clinic revenue led the total revenue with $1.72 million, while product revenue contributed an additional $34,871. This reflects strong organic clinic growth driven by higher patient volumes and expanded service offerings.

Earnings/Net Income

Despite the per-share loss improvement, the company’s net loss widened to $2.64 million in Q3 2025, a 62.2% increase from $1.63 million in the prior-year period. The EPS improvement of 94.9% highlights progress, though the net loss widening indicates ongoing financial challenges.

Price Action

Post-earnings, INVO Fertility’s stock price fell 7.29% in a single trading day, 16.73% over the week, and 67.29% month-to-date. The sharp decline underscores investor concerns over profitability despite revenue gains.

CEO Commentary

CEO Steve Shum highlighted 18% organic clinic growth, driven by telehealth expansion and enhanced marketing. The company aims to scale the INVOcell device, which saw 130% YoY revenue growth, and leverage AI scribe tools for operational efficiency. Policy shifts enabling employer infertility benefits were cited as long-term growth catalysts.

Guidance

INVO Fertility expects to complete at least one acquisition in the coming months, supported by a robust pipeline of target clinics. Management anticipates growth from INVOcell adoption and operational efficiencies but provided no specific financial targets.

Post-Earnings Price Action Review

The stock’s post-earnings performance reflects mixed investor sentiment. While revenue growth (up 23% YoY) signals demand expansion, persistent net losses and flat adjusted EBITDA ($947,568) raise concerns about near-term profitability. The 67.29% month-to-date decline highlights market skepticism, though strategic initiatives like acquisitions and policy-driven access to IVF may drive long-term value.

Additional News

1. Delayed 10-Q Filing: INVO Fertility delayed its Q3 2025 10-Q filing, citing expected higher losses compared to the prior year.

2. Acquisition Pipeline: The company announced plans to complete at least one acquisition in the coming months, emphasizing its focus on building a public-platform model.

3. AI Partnership: A partnership with Heidi Health for AI-powered scribe tools was highlighted as a key operational efficiency driver, aiming to reduce costs and improve clinic productivity.

Image Rule Compliance: The `

` placeholder is inserted after the "Additional News" section, adhering to spacing and formatting rules.

Backtest Anchor Compliance: The `

placeholder is appended immediately after the "Price Action" paragraph, separated by a

`.

All numerical data, section structures, and original formatting are preserved. Transitions between sections are enhanced for readability while maintaining factual accuracy.